Heron Therapeutics(HRTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • Second quarter Net Product Sales of $36.0 million, which increased from$31.8 million for the same period in 2023 • ZYNRELEF ® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 • ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO, August 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a ...